Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Zhiwen Xiao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8640-2067; OpenAlex author ID A5003906531. Sources: OpenAlex.

Their work

Papers
18 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: 3 papers · 2016: none · 2017: 2 papers · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 3 papers · 2023: 3 papers · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 18

  1. Glucose is a potential source of glutamate for glutamine-deprived pancreatic cancer cells with KRAS mutation Co-author DOI 10.3724/abbs.2026063↗
  2. Pancreatic Cancer: An Exocrine Tumor With Endocrine Characteristics. First author DOI 10.1097/sla.0000000000006168↗
  3. Efficacy of vitamin C on chemotherapy-related anemia in pancreatic cancer: study protocol for a randomized controlled trial. Co-author DOI 10.1186/s13063-024-08345-w↗
  4. Hyperglycemia predicts adverse prognosis in advanced pancreatic cancer patients. Co-author DOI 10.1007/s12020-022-03196-4↗
  5. Glutamine is a substrate for glycosylation and CA19-9 biosynthesis through hexosamine biosynthetic pathway in pancreatic cancer. Co-author DOI 10.1007/s12672-023-00628-z↗
  6. Glutamine deprivation induces ferroptosis in pancreatic cancer cells. Co-author DOI 10.3724/abbs.2023029↗
  7. SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.01.026↗
  8. Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2022.104016↗
  9. TGF-β1-induced RAP2 regulates invasion in pancreatic cancer. Co-author DOI 10.3724/abbs.2022015↗
  10. CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype. Co-author DOI 10.1016/j.canlet.2016.10.046↗
  11. Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. Co-author DOI 10.3892/ol.2016.5501↗
  12. Lymph node status predicts the benefit of adjuvant chemoradiotherapy for patients with resected pancreatic cancer. Co-author DOI 10.1016/j.pan.2015.03.012↗
  13. Blood neutrophil-lymphocyte ratio predicts survival in patients with advanced pancreatic cancer treated with chemotherapy. Co-author DOI 10.1245/s10434-014-4021-y↗
  14. Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. Co-author DOI 10.2147/dddt.s77597↗
  15. Molecular mechanism underlying lymphatic metastasis in pancreatic cancer. Co-author DOI 10.1155/2014/925845↗
  16. CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer. First author DOI 10.1007/s11605-013-2389-9↗
  17. Highly lymphatic metastatic pancreatic cancer cells possess stem cell-like properties. Co-author DOI 10.3892/ijo.2013.1780↗
  18. Development of a unique mouse model for pancreatic cancer lymphatic metastasis. Co-author DOI 10.3892/ijo.2012.1613↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Guopei Luo · 15 shared papers, 2012–2026 · strength 1.71
  2. Xianjun Yu · 16 shared papers, 2012–2024 · strength 1.57
  3. Quanxing Ni · 13 shared papers, 2012–2026 · strength 1.42
  4. Chen Liu · 11 shared papers, 2012–2023 · strength 0.74
  5. Kaizhou Jin · 8 shared papers, 2015–2022 · strength 0.68
  6. Xinzhe Zhu · 3 shared papers, 2023–2024 · strength 0.66
  7. Liang Liu · 7 shared papers, 2013–2022 · strength 0.49
  8. Huaxiang Xu · 3 shared papers, 2022–2023 · strength 0.46
  9. Weiding Wu · 3 shared papers, 2022 · strength 0.42
  10. Jiang Long · 8 shared papers, 2012–2017 · strength 0.36
  11. Zuqiang Liu · 7 shared papers, 2013–2017 · strength 0.33
  12. Jin Xu · 7 shared papers, 2012–2017 · strength 0.30
  13. Qinglin Fei · 2 shared papers, 2022 · strength 0.29
  14. He Cheng · 3 shared papers, 2017–2022 · strength 0.29
  15. Xinyue Wang · 1 shared paper, 2024 · strength 0.26
  16. Xuan Lin · 2 shared papers, 2022 · strength 0.26
  17. Zhenyu Liao · 2 shared papers, 2022 · strength 0.26
  18. Tianjiao Li · 2 shared papers, 2022 · strength 0.26
  19. Long‐Yun Ye · 2 shared papers, 2022 · strength 0.26
  20. Meng Guo · 4 shared papers, 2015–2017 · strength 0.22
  21. Jianfeng Luo · 1 shared paper, 2024 · strength 0.20
  22. Wenchao Gu · 1 shared paper, 2023 · strength 0.17
  23. Cheng He · 1 shared paper, 2023 · strength 0.17
  24. Zhengjie Dai · 1 shared paper, 2023 · strength 0.17
  25. Chen Liu · 1 shared paper, 2023 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.